Although microRNAs and EIF4G2 are both known to play pivotal roles in cancer progression, it remains unknown whether these pathways regulate chemosensitivity in a coordinated manner. Here, we show that miR-379 expression is significantly downregulated in chemoresistant nonsmall cell lung cancer (NSCLC) tissues and cells. Manipulation of miR-379 levels could alter the in vitro and in vivo cisplatin (CDDP) resistance in lung cancer (LCa) cells. Mechanistically, miR-379 potentiated LCa chemosensitivity via modulation of CDDP-induced apoptosis by directly targeting the EIF4G2 3 0 UTR. Additionally, we observed an inverse correlation between miR-379 and EIF4G2 expression in LCa tissues from patients with CDDP-based chemotherapy. Together, our findings shed new light on the potential involvement of miR-379/EIF4G2 cascade in the pathogenesis of CDDP resistance in LCa.
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Keywords: chemoresistance; cisplatin; EIF4F; lung cancer; miRNAs Lung cancer (LCa), in which~80% patients have nonsmall cell lung cancer (NSCLC), represents one of the leading cancer-related deaths worldwide [1] . For patients with unresectable LCa, systemic chemotherapy (such as cisplatin/CDDP-based chemotherapy) remains the standard first-line therapy. However, drug resistance compromises the therapeutic benefits frequently, thus remaining a major challenge to overcome in LCa treatment [2, 3] . Clearly, the mechanisms underlying chemoresistance in LCa, which have been proposed to range from inactivation of tumor suppressive factors, deregulation of DNA repair genes and cell cycle regulators to reduction in the intracellular drug accumulation [4] , involve molecular events at different levels and remain to be fully delineated.
MicroRNAs (miRNAs), a class of small noncoding RNA molecules that negatively regulate the expression of target genes by directly binding the three prime untranslated regions (3 0 UTR), regulate various pathophysiological conditions such as differentiation, morphogenesis, and carcinogenesis [5] . Recently, numerous studies have unanimously confirmed the crucial role of miRNAs in modulating sensitivity and resistance to chemotherapy. Of particular interest in NSCLC are miR-21, miR-17/92, miR-31, and miR-224 which act as oncomiRs, whereas Let-7 and miR-34b have been confirmed to serve as tumor suppressor miRs [6] . Nevertheless, it is important to understand that miRNA expression patterns and the corresponding effects are tissue and cell type specific, and a single miRNA may encompass multiple targets [7] . Therefore, it would be necessarily essential to explore further the differential miRNA expression profiles of various cell types constituting malignancy.
Aberrant expression of eukaryotic initiation factor 4F (EIF4F) components, including cap-binding protein EIF4E, scaffolding protein EIF4G, and ATP-dependent RNA helicase EIF4A, has been shown to play key roles in the pathogenesis of many cancers [8] . A recent advance in this field has shown that deregulation of EIF4G mediates a rate-limiting process that drives selective translation of many oncongenic proteins, thereby contributing to therapeutic resistance and tumor progression. For example, upregulation of EIF4G1 expression is closely associated with malignant cell transformation. Similarly, downregulation of eIF4GII by miR-520c-3p inhibits tumor progression in diffuse large B cell lymphoma [9] . However, little is currently known about the upstream regulating mechanisms of EIF4G expression.
In the current study, we demonstrated that miR-379 can potentiate chemosensitivity in LCa via modulation of CDDP-induced apoptosis by directly targeting EIF4G2. Overall, our work supports the notion that miR-379, acting as a tumor suppressor, might serve as a novel potential therapeutic target for NSCLC.
Materials and methods

Human patient tissues
Human sample studies have been approved by the local ethical committee and conform to the Declaration of Helsinki. Written informed consent was obtained from all patients. A total of 84 tumor tissues were collected from advanced NSCLC patients who received CDDP-based chemotherapy at First Hospital of Yulin City between January 2010 and December 2013. Samples, classified histologically by two professional pathologists, were defined as 'sensitive' and 'insensitive' groups according to the patient's responses assessed by medical image analysis and detection of serum tumor markers after four cycles of the CDDP chemotherapy, as described elsewhere [4] . Moreover, tissues from 20 patients with benign diseases (including pulmonary bullae and chronic granuloma) were used as controls.
Cell treatment
Nonsmall cell lung cancer cells (SPC-A1, SK-MES-1, H1299, and A549), a normal human bronchial epithelial cell line (16HBE), and HEK293T cell, obtained from ATCC (Manassas, VA, USA), were cultured in DMEM supplemented with 10% FBS (Invitrogen, Shanghai, China), 100 unitsÁmL À1 penicillin, and 100 lgÁmL À1 streptomycin (Sigma-Aldrich, Shanghai, China) in a humidified incubator at 37°C with 5% CO 2 . The CDDP-resistant A549 cells (A549/R) were established by gradual exposure to increasing concentrations of CDDP and were maintained in the above-mentioned medium containing 1 lgÁL
À1
CDDP [10] . To manipulate the expression levels of miR-379, cells were incubated with miR-379 mimics (10 nM) or antisense inhibitors (50 nM) (Sigma-Aldrich) in 100 lL culture medium, in the absence of serum and antibiotics. EIF4G2 knockdown was performed by transfecting cells with corresponding shRNA against EIF4G2 or with a control shRNA (ViGene Biosciences, Rockville, MD, USA). Forty-eight hours later, cells were harvested and subjected to other analyses.
Assessment of cell survival
Cells were cultured for 24 h, and then the culture medium was removed and CDDPs were added at the indicated concentrations. After another 24-h exposure, cell viability was evaluated using Vybrant Ò MTT Cell Proliferation Assay Kit (ThermoFisher, Shanghai, China). The IC50 value of CDDP in different groups was calculated accordingly [4] .
Apoptosis measurement
Cells were treated with different concentrations of CDDP as indicated. Twenty-four hours later, cells were harvested and an apoptotic ELISA kit (Roche Diagnostics, Suzhou, China) was used to quantitatively measure cytoplasmic histone-associated DNA fragments [11] . Final spectrophotometry was measured in triplicate at 405 nM using FLx800 TM Microplate Reader (BioTek, Beijing, China).
Colony formation assay
Approximately 500 cells per well were seeded in six-well plates (BD Falcon, Shanghai, China). At the end of 48 h of culture, CDDP was added. Three days later, the CDDPcontaining media was replaced with fresh media and all cultures were incubated for an additional 11 days until colonies were large enough to be clearly discerned. Colonies were finally stained for 5 min with a solution containing 0.5% crystal violet and 25% methanol, and the number of colonies was calculated [12] .
In vivo chemosensitivity assay
Tumor cells were resuspended in PBS at the concentration of 1 9 10 7 cellsÁmL À1 . About 0.1 mL of suspended cells was subcutaneously injected in 8-week-old nude mice (n = 5 mice/group). Mice injected with the equivalent volumes of PBS served as controls. After 12 days of cell inoculation, mice were injected intraperitoneally with CDDP at the dose of 4.0 mgÁkg À1 , once every other day, for a total of three doses [4] . Mice receiving 10% DMSO alone were treated as controls. Tumor growth was monitored every 4 days, and tumor volume was calculated using the equation
Quantitative reverse transcription PCR
Total RNA was isolated using MagMAX TM mirVana TM Total RNA Isolation Kit (ThermoFisher) according to the manufacturer's protocol. For miR-379 and EIF4G2 expression analysis, total RNA was retro transcribed with microRNA specific primers (3 0 -TATGTAACATGGTCCACTAACT 5 0 ) and EIF4G2 primers [9] using TaqMan microRNA and a QuantiTect Reverse Transcription Kit (QIAGEN, Shenzhen, China), respectively. Amplification of human U6 snRNA and 18S RNA served as internal control. The relative abundance of each target transcript was quantified using the comparative DDCt method.
Immunoblotting
Immunoblotting was carried out according to previous reports [13, 14] . Membranes were incubated with different primary antibodies including rabbit anti-EIF4G2 (Cell Signaling, Shanghai, China) and rabbit anti-b-ACTIN (Santa Cruz Biotechnology, Shanghai, China).
Luciferase reporter assay
Plasmids pLightSwitch-Luc-Blank and pLightSwitch-Luc-EIF4G2/3 0 UTR were obtained from SwitchGear Genomics (Shanghai, China). The site-directed mutagenesis of the miR-379 target-site was carried out using QuikChange Site-Directed Mutagenesis Kit (Agilent, Santa Clara, CA, USA). The constructs were sequenced and named pLightSwitch-Luc-EIF4G2/3 0 UTR-WT or pLightSwitch-Luc-EIF4G2/ 3 0 UTR-MU. For reporter assay, HEK293T cells were transfected with 100 ng of pLightSwitch-Luc-EIF4G2/ 3 0 UTR-WT or pLightSwitch-Luc-EIF4G2/3 0 UTR-MU as well as miR-379 mimics/miR-379 inhibitors (or corresponding controls) using Lipofectamine 2000 (Invitrogen). Two days later, cells were harvested and luciferase activity measurements were performed in LightSwitch Assay Reagents as per the manufacturer's protocol.
Statistical analysis
Data, presented as the mean AE SEM, were analyzed using Student's t-test (two-tailed) or one-way analysis of variance. The association between miR-379 expression and EIF4G2 level was assessed using the Pearson ChiSquare test. All statistical analyses were performed using the SPSS version 16.0 software package (SPSS Inc., Chicago, IL, USA). P < 0.05 was considered to be statistically significant.
Results
Downregulation of miR-379 expression in chemoresistant NSCLC
Previous study has identified miR-379 as the most downregulated miRNA in chemoresistant A549 cells [5] . To elaborate this, a total of 84 NSCLC tissues and 20 benign tissues were collected. RT-qPCR revealed that miR-379 expression was significantly decreased in the tumors (Fig. 1A) . More importantly, miR-379 expression was even more lower in chemoresistant tumors than that in chemosensitive tumors (Fig. 1B) .
To verify this at the in vitro level, we evaluated the miR-379 expression in four NSCLC cells, with the benign human bronchial epithelial cell line (16HBE) serving as a control. miR-379 level was significantly reduced in tumor cells compared to the control, with the lowest value being detected in the more aggressive H1299 and A549 cells (Fig. 1C) . Thus, miR-379 deficiency is correlated with the magnitude of malignancy. Consistent with the above observations, miR-379 level was gradually decreased with the concentration gradient of CDDP (Fig. 1D ). To ask whether miR-379 is directly involved in chemoresistance, we generated CDDP-resistant subline (A549/R). A549/R exhibited much less chemosensitivity to CDDP than the parental A549 cells (Fig. 1E ). In line with the clinical data, miR-379 expression was dramatically reduced in A549/ R than in A549 cells (Fig. 1F) . Together, miR-379 deficiency might have potential roles in the development of CDDP resistance in LCa.
Downregulation of miR-379 promotes chemoresistance in LCa
Next, we tried to study the direct role of miR-379 by manipulating its expression levels. Transfection with miR-379 mimics unregulated miR-379 level by~12.8 fold in A549/R cells ( Fig. 2A) . This upregulation significantly improved the chemosensitivity in A549/R cells, as revealed by measurement of IC50 (Fig. 2B) . Consistently, in the presence of various concentrations of CDDP exposure, the capacity of colony formation in A549/R cells was significantly impaired when compared with that in A549/R cells transfected with the empty control vector (miR-NC) (Fig. 2C) . Further apoptotic analysis demonstrated that the miR-379 upregulation-elicited impairment of colony formation capacity in A549/R cells may be caused by an invoked apoptosis upon CDDP exposure (Fig. 2D) . Finally, A549/R cells, which were transfected with miR-379 mimics and implanted into nude mice, grew into notably smaller tumors than A549/R cells that were transfected with miR-NC (Fig. 2E) . Thus, these results suggested that miR-379 has an inhibitory effect on tumor aggressiveness upon CDDP treatment. To further investigate whether impaired miR-379 expression is causative of or a result of chemoresistance in LCa, we knocked down miR-379 expression in A549 cells (Fig. 2F) . Notably, inhibition of miR-379 expression resulted in less chemosensitivity (Fig. 2G) , increased colony formation rate (Fig. 2H) , and compromised cell death (Fig. 2I) 379 inhibitors were apparently bigger than those formed from A549/miR-anti-NC cells during the late stage of CDDP treatment (Fig. 2J) . Collectively, the available data suggest that upregulation of miR-379 level could potentiate chemosensitivity in LCa.
Direct target of EIF4G2 3 0 UTR by miR-379 in LCa cells
By using an open access platform (www.microRNA. org), EIF4G2 was chosen as a preferred candidate target gene of miR-379. MirSVR (cutoff 0.1 or lower) and PhastCons (cutoff 0.57 or higher) are downregulation and conservation scores, respectively. Figure 3A showed the miR/EIF4G2 alignment: the mirSVR downregulation score is 1.3371 and the PhastCons score is 0.7528, predicting EIF4G2 as a very likely candidate target of miR-379. To validate this, we transfected A549/R cells with miR-379 mimics or miR-NC. Supplementation with exogenous miR-379 significantly suppressed EIF4G2 expression in A549/R cells (Fig. 3B,C) . Conversely, repression of miR-379 level by transfection with miR-379 inhibitors dramatically stimulated EIF4G2 expression in A549 cells (Fig. 3D,  E) . Because in silico analysis revealed that 3 0 UTR of human EIF4G2 contains a potential miR-379-binding site (Fig. 3A) , we cotransfected HEK 293T cells with pLightSwitch-Luc-EIF4G2/3 0 UTR-WT and miR-379 mimics or miR-NC. Forty-eight hours later, the reporter assay revealed that the luc activity was significantly suppressed by about 63.1% in HEK293 cells cotransfected with pLightSwitch-Luc-EIF4G2/3 0 UTR-WT and miR-379 mimics, compared with control (P < 0.05; Fig. 3F ). To further confirm that the EIF4G2 3 0 UTR is a direct target for miR-379, we mutated the miR-379-binding site and subcloned it into pLightSwitchLuc vector to generate pLightSwitch-Luc-EIF4G2/ 3 0 UTR-MU (Fig. 3G ). As expected, the mutations of EIF4G2 3 0 UTR prevented the alterations in the luciferase activity, regardless of the presence of miR-379 mimics or miR-379 inhibitors (Fig. 3H) . Thus, 3 0 UTR of EIF4G2 is likely a direct binding target of miR-379.
EIF4G2 inhibition mimics the antichemoresistance effect of miR-379 in LCa cells
Lastly, we tried to study whether inhibition of EIF4G2 expression could mimic the antichemoresistance effect of miR-379 in LCa cells. By using shRNA treatment, we knocked down the expression level of EIF4G2 by 65.7% in A549/R cells (Fig. 4A,B) . Interestingly, EIF4G2 suppression significantly improved the chemosensitivity (Fig. 4C,D) and resulted in a reduced in vivo tumor formation after long-term CDDP exposure (Fig. 4E) . Thus, downregulation of EIF4G2 could mimic the effect of miR-379 overexpression on the chemosensitivity of A549/R cells. Additionally, by using Pearson Chi-Square test, it was found that the relative miR-379 expression level was inversely correlated with EIF4G2 expression in LCa tissues from patients who received CDDP-based chemotherapy (Fig. 4F) . The last evidence further emphasizes the importance of miR-379/EIF4G2 cascade in the pathogenesis of LCa chemoresistance.
Discussion
Emerging data demonstrate a crucial involvement of miRNAs in regulating chemotherapeutic sensitivity [6, [15] [16] [17] . For example, upregulation of miR-138 increases CDDP sensitivity and augments CDDPinduced apoptosis via modulation of ERCC1, in A549 cells. Similarly, miR-451 and miR-630 could both serve as tumor suppressor miRNAs to improve cisplatin sensitivity. Contrarily, miR-31 acts as an oncomiR and promotes CDDP resistance through regulation of the membrane transporter ABCB9 [6] . Nevertheless, the data regarding deregulated miRNA and corresponding molecular mechanisms underlying chemoresistance remain relatively limited compared to extensively studied NSCLC. Herein, we demonstrated that reduced levels of miR-379 resulted in impaired sensitivity to CDDP-elicited apoptosis and thus promoted chemoresistance in A549 cells (Fig. 2) . Furthermore, we provide mechanistic clues that 3 0 UTR of EIF4G2, an important organizing protein in the recruitment of mRNA during translational initiation, was directly targeted by miR-379 binding (Fig. 3) . Additionally, enhanced EIF4G2 expression was negatively correlated with the decreased expression levels of miR-379 in clinical chemoresistant NSCLC tissues (Fig. 4) . Hence, by suppressing EIF4G2 protein expression, miR-379 may indirectly regulate EIF4G2-dependent pathways and collaboratively maintain chemosensitivity in LCa cells.
Recently, miR-379 has been reported to be downregulated in many human cancers, suggesting that miR-379 may function as a tumor suppressor [18] . In favor of this assumption, miR-379 expression is found to decrease significantly with increasing tumor stage and cancerous proliferation is reduced following miR-379 overexpression [19] . Similarly, miR-379 suppresses the tumor progression in osteosarcoma and hepatocellular carcinoma by targeting PDK1 [20] and FAK/AKT signaling [21] , respectively. Together with our observation that transfection with miR-379 mimics promoted CDDPinduced cell death in chemoresistant A549/R cells (Fig. 2) , the available data strongly suggest that the role of miR-379 as a tumor suppressor appeared relatively conserved. So far, there are only two reports describing the potential involvement of miR-379 in the pathogenesis of drug resistance. Genistein, a phytoestrogen abundant in soybean, indirectly regulates efflux pumps (such as P-glycoprotein and multidrug resistance-associated proteins 2 and 3) that play key roles in cancer chemoresistance, through downregulation of miR-379 in hepatocarcinoma [22] . Likewise, in malignant pleural mesothelioma cells, miR-379 can promote the drug sensitivity via direct modulation of IL-18 expression [23] . However, since a single miRNA may encompass multiple targets, alternative pathways should be further explored. In the current study, we explore the emerging role of miR-379 in CDDP resistance of human LCa cells. Our gain-of-function studies show that upregulation of miR-379 level can significantly improve CDDP sensitivity in chemoresistant A549/R cells by inducing apoptosis enhancement. Meanwhile, by using loss-offunction techniques, we found that inhibition of endogenous miR-379 expression results in a notable CDDP resistance in chemosensitive A549 cells. More importantly, by analyzing LCa tissues obtained from patients who received CDDP-based chemotherapy, we observe that the relative expression levels of miR-379 in chemosensitive tumor tissues was significantly higher than those in chemoresistant tumor tissues. Overall, these results collectively provide new insights into the molecular functions of miR-379 as a tumor suppressor in chemotherapeutic resistance, and also point out its potential as biomarkers for disease stratification and new therapeutic strategies for personalized treatments.
Compelling evidence has established that targeting regulatory hubs in the upstream signaling network instead of targeting individual genetic alterations should be more effective in treating cancer progression [6] . To this end, disruption of the translational machinery, which usually occurs through modification in consecutive stages of translation, has been emerging as a major contributor to the pathogenesis of chemoresistance [24] . Eukaryotic translation initiation factor EIF5A2, acting mainly as an elongation factor during mRNA translation, promotes chemoresistance to doxorubicin via regulation of epithelial mesenchymal transition in colorectal cancer [25] . In addition, upregulation of EIF2a phosphorylation could enhance doxorubicin-mediated apoptosis and potentiate chemosensitivity in breast cancer cells [26] . Thus, regulation of translation initiation factor complex appeared to be bifunctional in the alteration of chemosensitivity. Of particular interest, because many oncogenic signaling pathways converge on EIF4F complex (including EIF4E, EIF4G, and EIF4A) that mediates a rate-limiting process at the level of translational initiation, targeting EIF4F component-mediated translation is considered a novel and promising anti-chemoresistance strategy [27] . Suppression of EIF4G2 by miR-520c-3p impediments cancerous progression in diffuse large B cell lymphoma [9] , lending strong support to the above notion. Nevertheless, the transcriptional or post-transcriptional mechanisms responsible for controlling EIF4G2 expression in response to DNA damage are poorly understood. Our results extend these understanding by identifying EIF4G2 3 0 UTR as the direct binding target of miR-379 (Fig. 3) . The current study also points out that incorporation of synergistic actions of both transcriptional repression (miRNA) and translational regulation (EIF4F complex) mechanisms may play an unexpected pivotal role in the development of LCa chemoresistance. To conclude, our work establishes a functional link between miR-379 and EIF4G2 in LCa, and demonstrates that miR-379 can potentiate chemosensitivity in LCa via modulation of CDDP-induced apoptosis by directly targeting EIF4G2. Together, miR-379 signature associated with alteration of EIF4G2 expression may be used to predict the chemotherapeutic response in LCa patients.
